Genetic variability in response to clopidogrel therapy and its clinical implications

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245

Contemporary issues in atherothrombosis

Issue: 2011: 105/Supplement 1
Pages: S55-S59

Genetic variability in response to clopidogrel therapy and its clinical implications

L. Yukhanyan (1), M. K. Freynhofer (1), J. Siller-Matula (2), K. Schrör (3), K. Huber (4)

(1) 3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria; (2) Department of Cardiology, Medical University of Vienna, Vienna, Austria; (3) Institute for Pharmacology und Clinical Pharmacology, Heinrich-Heine-Universität, Düsseldorf, Germany; (4) 3rd Medical Department with Cardiology and Emergency Medicine, Wilhelminen Hospital, Vienna, Austria


thrombosis, gene mutations, coronary syndrome, Antiplatelet agents


This article concentrates on individual genetic differences responsible for variations of action of clopidogrel, which have been found to be partially responsible for increased cardiovascular events in patients with coronary artery disease under dual antiplatelet therapy. According to these results, genotyping for the relevant gene polymorphisms, especially for the CYP2C19 loss-of-function alleles, has been discussed to be an effective method of individualising and optimising clopidogrel treatment. However, due to the facts that 1) there are no prospective studies demonstrating a clinical benefit of personalising antiplatelet therapy based on genotyping; 2) CYP2C19 polymorphisms account for only approximately 12% of variability in clopidogrel platelet response; 3) the positive predictive value of CYP2C19 loss-of-function polymorphisms for cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention is only approximately 12% – 20%; 4) it is likely that other clinical factors and risk constellations might be of greater clinical importance; and 5) it is unknown whether a specific genetic polymorphism is capable of influencing outcome for the individual patient; genetic profiling cannot be recommended for routine use at present but will remain of considerable scientific interest.

You may also be interested in...

Thomas Cuisset 1, Corinne Frere 2, Jacques Quilici 1, Pierre-Emmanuel Morange 2, Noémie Saut 2, Marie Romero-Barra 2, Laurence Camoin 3, Marc Lambert 1, Irène Juhan-Vague 2, Jean-Louis Bonnet 1, Marie-Christine Alessi2

Thromb Haemost 2007 97 2: 212-217


Muhammad R. Marwali, Jawahar L. Mehta

Thromb Haemost 2006 96 4: 401-406


Online Supplementary Material

J. D. Eicher (1, 2), M.-H. Chen (1, 2), A. N. Pitsillides (2), H. Lin (3), N. Veeraraghavan (4), J. A. Brody (5), G. A. Metcalf (6), D. M. Muzny (6), R. A. Gibbs (6), D. M. Becker (7), L. C. Becker (7, 8), N. Faraday (9), R. A. Mathias (10), L. R. Yanek (7), E. Boerwinkle (6, 7), L. A. Cupples (2, 8), A. D. Johnson (1, 2)

Thromb Haemost 2017 : -